TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07723703: Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Sponsor: Amphista Therapeutics Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 54 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07723703 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07723703 Rescue Dossier →